ERBB2 and neoplasm: We tested if ADCK2 pathogenetic or unknown variants or ADCK2 mRNA or protein expression would have associations with tumour size, nodal status, the presence of distant metastases at diagnosis, tumour multifocality, ER or PR expression, Ki-67 expression, HER2 amplification, immunohistochemical synaptophysin or chromogranin expression, primary tumour size (in mm), or parity.